Advertisement

Archives of Virology

, Volume 120, Issue 1–2, pp 1–17 | Cite as

Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles

  • S. Kit
  • Malon Kit
  • R. D. DiMarchi
  • Sheila P. Little
  • C. Gale
Original Papers

Summary

Modified-live, attenuated infectious bovine rhinotracheitis (IBR) hybrid virus vaccines have been constructed by inserting in the major IBRV glycoprotein g III gene chemically synthesized deoxyribonucleotide sequences encoding the bovine growth hormone signal sequence and monomeric or dimeric forms of the foot and mouth disease virus (FMDV) VP 1 epitope sequences. The foreign DNA sequences were inserted at the N-terminal end of the IBRV g III coding sequence and were driven by the IBRV g III promoter. The sequences encoding the first 38 and the first 21 amino acids of the IBRV g III were deleted from the hybrid viruses containing inserts of the monomeric and dimeric FMDV epitope sequences, respectively, to avoid redundant signal sequences. Plaque immunoassay experiments with guinea pig and bovine anti-FMDV peptide antisera, and with anti-IBRV g III monoclonal antibodies demonstrated that IBRV-FMDV fusion proteins were expressed in virus-infected MDBK cells. Immunoelectron microscopy analyses demonstrated that the IBRV-FMDV fusion proteins were expressed as repeated structures on the surface of virus particles. Experiments showed that the recombinant IBRV-FMDV viruses protected cattle from IBRV (Cooper) challenge and induced anti-FMDV peptide antibodies, thereby demonstrating that the FMDV epitopes were expressed in vivo.

Keywords

Virus Particle Virus Vaccine Immunoelectron Microscopy Mouth Disease MDBK Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bachrach HL, Moore DM, McKercher PD, Polatnick J (1975) Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus. J Immunol 115: 1636–1641Google Scholar
  2. 2.
    Bittle JL, Houghten RA, Alexander H, Shinnick TM, Sutcliffe JG, Lerner RA, Rowlands DJ, Brown F (1982) Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 298: 30–33Google Scholar
  3. 3.
    Brockjuijsen MP, Van Rijn JMM, Blom AJM, Pouwels PH, Enger-Valk BE, Brown F, Francis MJ (1987) Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals. J Gen Virol 68: 3137–3143Google Scholar
  4. 4.
    Carrillo C, Dopazo J, Moya A, Gonzalez M, Martinez MA, Saiz JC, Sobrino F (1990) Comparison of vaccine strains and the virus causing the 1986 foot-and-mouth disease outbreak in Spain: epizootiological analyses. Virus Res 15: 45–56Google Scholar
  5. 5.
    Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, Highfield PE, Rowlands DJ, Brown F (1987) Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330: 381–384Google Scholar
  6. 6.
    DiMarchi R, Brooke G, Gale C, Cracknell V, Doel T, Mowat N (1986) Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 232: 639–641Google Scholar
  7. 7.
    Doel TR, Gale C, Brooke G, DiMarchi R (1988) Immunization against foot-and-mouth disease with synthetic peptides representing the C-terminal region of VP 1. J Gen Virol 69: 2403–2406Google Scholar
  8. 8.
    Doel TR, Gale C, Do Amaral CMCF, Mulcahy G, DiMarchi R (1990) Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus. J Virol 64: 2260–2264Google Scholar
  9. 9.
    Fitzpatrick DR, Redmond MJ, Attah-Poku SK, Van Drunen Little-Van den Hurk S, Babiuk LA, Zamb TJ (1990) Mapping of 10 epitopes on bovine herpesvirus type-1 glycoproteins g I and g III. Virology 176: 145–157Google Scholar
  10. 10.
    Fitzpatrick DR, Babiuk LA, Zamb TJ (1989) Nucleotide sequence of bovine herpesvirus type 1 glycoprotein g III, a structural model for g III as a new member of the immunoglobulin superfamily, and implications for the homologous glycoproteins of other herpesviruses. Virology 173: 46–57Google Scholar
  11. 11.
    Francis MJ, Clarke BE (1989) Peptide vaccines based on enhanced immunogenicity of peptide epitopes presented with T-cell determinants or hepatitis B core protein. Methods Enzymol 178: 659–676Google Scholar
  12. 12.
    Gait MJ (ed) (1984) Oligonucleotide syntheses: a practical approach. IRL Press, Washington, DCGoogle Scholar
  13. 13.
    Kleid DG, Yansura D, Small B, Dowbenko D, Moore DM, Grubman MJ, McKercher PD, Morgan DO, Robertson BH, Bachrach HL (1981) Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science 214: 1125–1129Google Scholar
  14. 14.
    Kit M, Kit S, Otsuka H (1989) Infectious bovine rhinotracheitis mutants, vaccines containing same, methods for the production of same, and methods for the use of same. European Patent Application No. 03166658. Published May 25, 1989Google Scholar
  15. 15.
    Kit S (1989) Recombinant-derived modified-live herpesvirus vaccines. In: Attasi MZ (ed) Immunobiology of proteins and peptides, vol 5. Vaccines, mechanisms, design, and applications. Plenum, New York, pp 219–236Google Scholar
  16. 16.
    Kit S (1988) Genetically engineered pseudorabies and infectious bovine rhinotracheitis virus vaccines. In: Lasky L (ed) Technological advances in vaccine development. AR Liss, New York, pp 183–195 (UCLA Symposium on Molecular and Cellular Biology, vol 84)Google Scholar
  17. 17.
    Kit S, Kit M, McConnell S (1986) Intramuscular and intravaginal vaccination of pregnant cows with thymidine kinase-negative, temperature-resistant infectious bovine rhinotracheitis virus (bovine herpesvirus 1). Vaccine 4: 55–61Google Scholar
  18. 18.
    Kit S, Qavi H (1983) Thymidine kinase (TK) induction after infection of TK-deficient rabbit cell mutants with bovine herpesvirus type-1 (BHV-1): isolation of TK BHV-1 mutants. Virology 130: 381–389Google Scholar
  19. 19.
    Kit S, Qavi H, Gaines JD, Billingsley P, McConnell S (1985) Thymidine kinase-negative bovine herpesvirus type-1 mutant is stable and highly attenuated in calves. Arch Virol 86: 63–83Google Scholar
  20. 20.
    Kit M, Kit S, Little S, DiMarchi R, Gale C (1991) Infectious bovine rhinotracheitis virus vector which expresses foot-and-mouth disease virus epitopes on surface of virus particles and virus-infected cells. In: Brown F, Chanock RM, Ginsberg HS, Lerner RA (eds) Vaccines 91. Modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, pp 327–331Google Scholar
  21. 21.
    Leary TP, Splitter GA (1990) Recombinant herpesviral proteins produced by cell-free translation provide a novel approach for the mapping of T lymphocyte epitopes. J Immunobiol 145: 718–723Google Scholar
  22. 22.
    Newton SE, Francis MJ, Brown F, Appleyard G, Mackett M (1986) Expression of a foot-and-mouth disease virus immunogenic site sequence in vaccinia virus. In: Lerner RA, Chanock RM, Brown F (eds) Vaccines 86. Cold Spring Habor Laboratory, Cold Spring Harbor, NY, pp 303–309Google Scholar
  23. 23.
    Otsuka H, Hazen M, Kit M, Qavi H, Kit S (1981) Cloning of marmoset herpesvirus thymidine kinase and analyses of the boundaries of the coding region. Virology 113: 196–213Google Scholar
  24. 24.
    Otsuka H, Kit S (1984) Nucleotide sequence of the marmoset herpesvirus thymidine kinase gene and predicted amino acid sequence of thymidine kinase polypeptide. Virology 135: 316–330Google Scholar
  25. 25.
    Parry NR, Barnett PV, Ouldridge EJ, Rowlands DJ, Brown F (1981) Neutralizing epitopes of type O foot-and-mouth disease virus. II mapping of three conformational sites with synthetic peptide reagents. J Gen Virol 70: 1493–1503Google Scholar
  26. 26.
    Pereira HG (1981) Foot-and-mouth disease. In: Gibbs RPJ (ed) Virus diseases of food animals, vol 2. Academic Press, New York, pp 333–363Google Scholar
  27. 27.
    Pignatti PR, Cassai E, Meneguzzi G, Chenciner N, Milanesi G (1979) Herpes simplex virus DNA isolation from infected cells with a novel procedure. Virology 93: 250–264Google Scholar
  28. 28.
    Strohmaier K, Franze R, Adam K-H (1982) Location and characterization of the antigenic portion of the FMDV immunizing protein. J Gen Virol 59: 295–306Google Scholar
  29. 29.
    Su T-Z, Raafat El-Gewely M (1988) A multisite-directed mutagenesis using T 7 DNA polymerase: application for reconstructing a mammalian gene. Gene 69: 81–89Google Scholar
  30. 30.
    USDA-APHIS (1990) Foreign animal disease report of the USDA-APHIS No. 18-2, Summer, Hyattsville, MDGoogle Scholar
  31. 31.
    Wild TF, Burroughs JN, Brown F (1969) Surface structure of foot-and-mouth disease virus. J Gen Virol 4: 313–320Google Scholar
  32. 32.
    Xie Q-C, McCahon D, Crowther JR, Belsham GJ, McCullough KC (1987) Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol 68: 1637–1647Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • S. Kit
    • 1
  • Malon Kit
    • 2
  • R. D. DiMarchi
    • 3
  • Sheila P. Little
    • 3
  • C. Gale
    • 3
  1. 1.Division of Biochemical VirologyBaylor College of MedicineHouston
  2. 2.NovaGene, Inc.Houston
  3. 3.Eli Lilly Research LaboratoriesIndianapolisUSA

Personalised recommendations